357 related articles for article (PubMed ID: 27570551)
1. Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Kurian SM; Novais M; Whisenant T; Gelbart T; Buxbaum JN; Kelly JW; Coelho T; Salomon DR
Theranostics; 2016; 6(11):1792-809. PubMed ID: 27570551
[TBL] [Abstract][Full Text] [Related]
2. Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Nov; 16(11):4104-4112. PubMed ID: 28922609
[TBL] [Abstract][Full Text] [Related]
3. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.
Kollmer J; Sahm F; Hegenbart U; Purrucker JC; Kimmich C; Schönland SO; Hund E; Heiland S; Hayes JM; Kristen AV; Röcken C; Pham M; Bendszus M; Weiler M
Neurology; 2017 Aug; 89(5):475-484. PubMed ID: 28679600
[TBL] [Abstract][Full Text] [Related]
4. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.
Olsson M; Norgren N; Obayashi K; Plante-Bordeneuve V; Suhr OB; Cederquist K; Jonasson J
BMC Med Genet; 2010 Sep; 11():130. PubMed ID: 20840742
[TBL] [Abstract][Full Text] [Related]
5. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
7. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
8. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.
Teixeira AC; Saraiva MJ
J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy.
Castro J; Miranda B; Castro I; de Carvalho M; Conceição I
Clin Neurophysiol; 2016 May; 127(5):2222-7. PubMed ID: 27072093
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of familial amyloid polyneuropathy].
Adams D; Samuel D; Slama M
Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis: a review of its use in familial amyloid polyneuropathy.
Scott LJ
Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
[TBL] [Abstract][Full Text] [Related]
12. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
13. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
14. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y
Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
[TBL] [Abstract][Full Text] [Related]
16. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
17. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
18. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.
Jiang X; Labaudinière R; Buxbaum JN; Monteiro C; Novais M; Coelho T; Kelly JW
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33597308
[TBL] [Abstract][Full Text] [Related]
19. Kidney and anemia in familial amyloidosis type I.
Beirão I; Lobato L; Costa PM; Fonseca I; Mendes P; Silva M; Bravo F; Cabrita A; Porto G
Kidney Int; 2004 Nov; 66(5):2004-9. PubMed ID: 15496172
[TBL] [Abstract][Full Text] [Related]
20. Family dynamics in transthyretin-related familial amyloid polyneuropathy Val30Met: Does genetic risk affect family functioning?
Lopes A; Rodrigues C; Fonseca I; Sousa A; Branco M; Coelho T; Sequeiros J; Freitas P
Clin Genet; 2018 Nov; 94(5):401-408. PubMed ID: 30019395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
